Advertisement

Topics

Crescendo Biologics Ltd Company Profile

03:35 EDT 26th September 2017 | BioPortfolio

Crescendo Biologics will apply highly innovative antibody fragment technologies to the development of new targeted therapeutics. The Crescendo transgenic mouse platform under development has the potential to rapidly and predictably generate high-affinity human heavy chain antibodies that readily yield VH fragments that have no requirement for humanisation. This is combined with a powerful in vitro ribosome display technology which offers significant advantages over existing approaches in antibody optimisation. VH fragments provide great flexibility as a starting point for the development of new targeted therapeutics combining the specificity and binding affinity of antibodies with certain desirable characteristics of small molecules.


News Articles [590 Associated News Articles listed on BioPortfolio]

Crescendo Biologics appoints new Chief Business Officer

Crescendo Biologics Ltd (Crescendo) announced that Edward J. “Tad” Stewart has joined the company as Chief Business Officer. Dr. Peter Pack, CEO of Crescendo Biologics commented: “Crescendo’s...

Appointments: Tiziana, Ergomed, Kymab, Crescendo, Ablynx, Axcella and Alexion.

This week's roundup includes CEO appointments by Tiziana and Ergomed and executive appointments by Crescendo Biologics, Ablynx, Alexion and Axcella...   

Crescendo Biologics appoints Edward Stewart as chief business officer

He joins the Cambridge, UK-based firm from Merrimack Pharmaceuticals

Crescendo Biologics Appoints Edward J. Stewart as Chief Business Officer

Cambridge, UK, 14 June 2017 – Crescendo Biologics Ltd (Crescendo), a company developing highly potent and differentiated Humabody® therapeutics, today announced that Edward J. “Tad&r...

Novavax: Catalysts Building Toward A Crescendo

Multibiomarker disease test showed efficacy in prediction of RA joint damage

MADRID — A new multibiomarker disease test, in combination with clinical measures, may be effective in predicting joint damage in patients with rheumatoid arthritis, according to data presented at t...

Publication of the Securities Note Having Obtained Visa No. 17-297 of the AMF in Connection with the Capital Increase of GenSight Biologics

NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA AND JAPAN. Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), ("GenSight Biologics...

Heat Biologics, Inc.: Dr. Jeff Hutchins Appointed Chief Operating Officer for Heat Biologics

DURHAM, NC / ACCESSWIRE / July 3, 2017 / Heat Biologics, Inc. ("Heat") (Nasdaq: HTBX), a leader in the development of novel therapies designed to activate a patient's immune system against cancer, ...

Drugs and Medications [3 Associated Drugs and Medications listed on BioPortfolio]

Standardized cat pelt [Jubilant HollisterStier LLC]

ALLERGENIC EXTRACT STANDARDIZED CAT PELT AP ACETONE PRECIPITATED

Standardized cat hair [Jubilant HollisterStier LLC]

ALLERGENIC EXTRACT STANDARDIZED CAT HAIR AP Acetone Precipitated

Cinryze [ViroPharma Biologics]

These highlights do not include all the information needed to use CINRYZE™ safely and effectively. See full prescribing information for CINRYZE.CINRYZE™ (C1 Esterase Inhibitor [Human]) For Intrave...

PubMed Articles [112 Associated PubMed Articles listed on BioPortfolio]

Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.

Biologic disease-modifying anti-rheumatic drugs (DMARDs: referred to as biologics) are effective in treating rheumatoid arthritis (RA), however there are few head-to-head comparison studies. Our syste...

Prolongation of biologic dosing intervals in patients with stable psoriasis: a feasibility study.

Biologics are usually licensed according to the "one dose fits all" principle. It is therefore suspected that a significant number of psoriasis patients are overtreated. However, evidence for successf...

Biosimilars: biologics that meet patients' needs and healthcare economics.

Biologics have revolutionized medical care, yet uniform access to these effective medicines remains difficult due to the increasing costs of healthcare. As patent exclusivity on the early biologics wa...

The expanding field of biologics in the management of chronic urticaria.

Chronic urticaria (CU) is the occurrence of urticaria with or without angioedema for at least 6 weeks. Management has traditionally involved antihistamines as first-line therapy with various alternati...

Treatment of rheumatoid arthritis with biologics may exacerbate HTLV-1-associated conditions: A case report.

There are roughly 5 to 10 million persons infected with human T-lymphotropic virus type 1 (HTLV-1) worldwide, and the safety of treating this population with biologics remains poorly understood.

Clinical Trials [61 Associated Clinical Trials listed on BioPortfolio]

Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database

The patients included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health plan...

Golimumab Safety and Surveillance Program Using the Ingenix NHI Database

The participants included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health ...

Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease

"RUN-CD" is an investigator initiated "Non interventional Trial" on biologics in Crohn´s Disease (CD) patients in Germany with a prospective documentation of effectiveness in induction an...

Tight Control Dose Reductions of Biologics in Psoriasis Patients With Low Disease Activity

Rationale/hypothesis: Moderate-to-severe psoriasis can be treated with biologics. Objective To investigate whether the dose of biologics can be reduced in patients with psoriasis with sta...

Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis

To estimate the real-world effectiveness of approved biologics in subjects with moderate-to-severe plaque psoriasis who are either starting or switching biologic medication.

Companies [240 Associated Companies listed on BioPortfolio]

Crescendo Biologics Ltd

Crescendo Biologics will apply highly innovative antibody fragment technologies to the development of new targeted therapeutics. The Crescendo transgenic mouse platform under development has the p...

Crescendo Pharmaceuticals

Crescendo was formed by ALZA for the purpose of selecting and developing human pharmaceutical products (the "Crescendo Products") and commercializing such products, most likely through licensing to AL...

Crescendo Bioscience, Inc.

Crescendo Bioscience is a molecular diagnostics company focused in rheumatology and located in South San Francisco, CA. Crescendo Bioscience develops quantitative, objective, biol...

Crescendo Bioscience

Crescendo Bioscience is a molecular diagnostics company focused in rheumatology and located in South San Francisco, CA. Crescendo Bioscience is developing quantitative, objective,...

Burst Biologics

Burst Biologics is a rapidly growing Biotechnology Company and federally registered tissue bank located in Boise, Idaho. Burst Biologics is a developer of effective tissue process...

More Information about "Crescendo Biologics Ltd" on BioPortfolio

We have published hundreds of Crescendo Biologics Ltd news stories on BioPortfolio along with dozens of Crescendo Biologics Ltd Clinical Trials and PubMed Articles about Crescendo Biologics Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Crescendo Biologics Ltd Companies in our database. You can also find out about relevant Crescendo Biologics Ltd Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record